Calidi Biotherapeutics, Inc. key statistics and ratios

In fiscal 2022, Calidi Biotherapeutics, Inc. had an operating margin of -51395.6% and a current ratio of 0.02. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Calidi Biotherapeutics, Inc.: financial ratios, annual
Fiscal year	2022Dec 2022
Operating margin	<−999%
Net margin	<−999%
Return on assets	−979.1%
Asset turnover	0.02
Current ratio	0.02
Interest cover (operating income ÷ interest)	n/m
R&D as % of revenue	>999%
SG&A as % of revenue	>999%

Calidi Biotherapeutics, Inc.: financial ratios, quarterly
Quarter	2022 Q4Dec 2022
Current ratio	0.02

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Calidi Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Calidi Biotherapeutics, Inc.